Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 8152526, 8 pages
https://doi.org/10.1155/2017/8152526
Research Article

Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells

1Department of Neurosurgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
2Department of Neurosurgery, Yancheng City No. 1 People’s Hospital, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng, China
3Department of Endocrinology, Yancheng Third Hospital, The Affiliated Hospital of Southeast University Medical College, Yancheng, China

Correspondence should be addressed to Ning Liu; moc.621@3580gninuil

Received 15 February 2017; Accepted 28 June 2017; Published 13 August 2017

Academic Editor: Yoshiyuki Kimura

Copyright © 2017 Feng Jia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Wen, S. Guang, M. Binbin, H. Xiangcheng, D. Xin, and Z. Bo, “Chemotherapy for adults with malignant glioma: a systematic review and network meta-analysis,” Turkish Neurosurgery, vol. 27, no. 2, pp. 174–181, 2015. View at Publisher · View at Google Scholar
  2. E. L. Diamond, G. W. Corner, A. De Rosa, W. Breitbart, and A. J. Applebaum, “Prognostic awareness and communication of prognostic information in malignant glioma: a systematic review,” Journal of neuro-oncology, vol. 119, no. 2, pp. 227–234, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Liu, X. Chen, J. Sun et al., “The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials,” Medicine, vol. 93, no. 25, p. e164, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Serkies, E. Wȩgrzynowicz, and J. Jassem, “Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: Case report and review of the literature,” Archives of Gynecology and Obstetrics, vol. 283, no. 1, pp. S97–S100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. G. K. Schwartz, K. Winter, B. D. Minsky et al., “Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114),” Journal of Clinical Oncology, vol. 27, no. 12, pp. 1956–1962, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Jeyapalan, J. Boxerman, J. Donahue et al., “Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a Brown University Oncology Group Study,” American journal of clinical oncology, vol. 37, no. 5, pp. 444–449, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Pipas, L. P. Meyer, C. H. Rhodes et al., “A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma,” Journal of Neuro-Oncology, vol. 71, no. 3, pp. 301–305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Liebmann, J. A. Cook, and J. B. Mitchell, “Cremophor EL, solvent for paclitaxel, and toxicity,” The Lancet, vol. 342, no. 8884, p. 1428, 1993. View at Google Scholar · View at Scopus
  9. Y. Li, K. Chen, L. Li, R. Li, J. Zhang, and W. Ren, “Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway,” Tumor Biology, vol. 36, no. 12, pp. 9823–9828, 2015. View at Publisher · View at Google Scholar
  10. X. Yang, J. Shen, Y. Gao et al., “Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis,” International Journal of Cancer, vol. 137, no. 8, pp. 2029–2039, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Ramanathan, K.-Y. Jan, C.-H. Chen, T.-C. Hour, H.-J. Yu, and Y.-S. Pu, “Resistance to paclitaxel is proportional to cellular total antioxidant capacity,” Cancer Research, vol. 65, no. 18, pp. 8455–8460, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Laurent, C. Nicco, C. Chereau, B. Weill, and F. Batteux, “Controlling tumor growth by modulating endogenous production of reactive oxygen species,” Cancer Research, vol. 65, no. 3, pp. 948–956, 2005. View at Google Scholar
  13. I. Khan, A. Qayum, and Z. Qureshi, “Study of the hypotensive action of berbamine, an alkaloid isolated from berberis lycium,” Life Sciences, vol. 8, no. 17, pp. 993–1001, 1969. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Wang, H. Zhao, Y. Chen, F. Xue, F. Zhou, and J. Lee, “A study on the hypotensive action and mechanism of berbamine hydrochloride,” Yao Xue Xue Bao, vol. 4, pp. 248–250, 15. View at Publisher · View at Google Scholar
  15. F. Yang, S. Nam, C. E. Brown et al., “A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling,” PLoS One, vol. 4, article e94443, 9. View at Google Scholar
  16. S. Nam, J. Xie, A. Perkins et al., “Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells,” Molecular Oncology, vol. 6, no. 5, pp. 484–493, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Liu, Y. Zhang, Y. Chen et al., “A novel calmodulin antagonist O-(4-ethoxyl-butyl)-berbamine overcomes multidrug resistance in drug-resistant MCF-7/ADR breast carcinoma cells,” Journal of Pharmaceutical Sciences, vol. 99, no. 7, pp. 3266–3275, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Jin and Y. Wu, “Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/smad signaling,” Anatomical Record, vol. 297, no. 5, pp. 802–809, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Chou and P. Talalay, “Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors,” Advances in Enzyme Regulation, vol. 22, pp. 27–55, 1984. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Yang, S. Nam, R. Zhao et al., “A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associatedwith activation of JNK/AP-1 signaling,” Cancer Biology and Therapy, vol. 14, no. 11, pp. 1024–1031, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Xu, K. Nakano, H. Iwasaki et al., “Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer,” Cancer Letters, vol. 306, no. 2, pp. 151–160, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Kim, Y. Juhnn, and Y. Song, “Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells,” Annals of the New York Academy of Sciences, vol. 1095, no. 1, pp. 82–89, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Mabuchi, M. Ohmichi, A. Kimura et al., “Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel,” Journal of Biological Chemistry, vol. 277, no. 36, pp. 33490–33500, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Wang, Q. Liu, Y. Zhang et al., “Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action,” Molecular Cancer, vol. 8, article 1476, p. 81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. H. P. Du, J. K. Shen, M. Yang et al., “4-Chlorobenzoyl berbamine induces apoptosis and G2/M cell cycle arrest through the PI3K/Akt and NF-kappaB signal pathway in lymphoma cells,” Oncology Reports, vol. 3, pp. 709–716, 23. View at Google Scholar